Production (Stage)
Lexaria Bioscience Corp.
LEXX
$0.97
$0.01531.60%
NASDAQ
| 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -39.65% | -0.35% | -23.75% | -22.62% | -174.32% |
| Total Depreciation and Amortization | 313.04% | -77.00% | 61.29% | 13.76% | -3.11% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 209.26% | 43.86% | 21.97% | -77.44% | 5,252.56% |
| Change in Net Operating Assets | -133.06% | 687.36% | -201.78% | 128.18% | 19,175.00% |
| Cash from Operations | -139.27% | 45.05% | -44.10% | -49.41% | -104.34% |
| Capital Expenditure | -- | 100.00% | 42.79% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 30.47% | -111.36% | 50.38% | -20.91% | 61.40% |
| Cash from Investing | 30.47% | 26.19% | 45.69% | -216.36% | 61.40% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 14,336.75% | -99.73% | -- | -100.00% | 46.06% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 14,336.75% | -99.73% | -- | -100.00% | 46.06% |
| Foreign Exchange rate Adjustments | 139.03% | -2,878.13% | -252.38% | 275.00% | 95.20% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -16.65% | -201.96% | 180.56% | -152.19% | 36.44% |